Cubist Pharmaceuticals Acquires Calixa Therapeutics for $92,500,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5ce6f651-f982-4d53-a5ad-304b4d417d27&Preview=1 - Date
12/14/2009 - Company Name
Calixa Therapeutics - Mailing Address
12481 High Bluff Drive San Diego, CA 92130 - Company Description
Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community. - Website
http://www.calixainc.com - Transaction Type
M&A - Transaction Amount
$92,500,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
The deal includes a $92.5 up-front cash payment, plus up to $310 million in earnout payments.
